|
|
Early-life exposure to perfluorinated alkyl substances modulates lipid metabolism in progression to celiac disease |
|---|---|
| Author: | Sinisalu, Lisanna1; Sen, Partho2; Salihović, Samira1,3; |
| Organizations: |
1School of Science and Technology, Örebro University, Örebro, Sweden 2Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland 3School of Medical Sciences, Örebro University, Örebro, Sweden
4Finnish Institute for Health and Welfare, Public Health Promotion Unit, Helsinki, Helsinki, Finland
5Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland 6Tampere University Hospital, Research, Development and Innovation Center, Tampere, Finland 7Tampere Center for Child Health Research, Tampere University Hospital, Tampere, Finland 8Faculty of Medicine Health Technology, Tampere University, Tampere, Finland 9Fimlab Laboratories, Pirkanmaa Hospital District, Tampere, Finland 10Immunogenetics Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland 11Clinical Microbiology, Turku University Hospital, Turku, Finland 12Institute of Biomedicine, Centre for Integrative Physiology and Pharmacology, And Centre for Population Health Research, University of Turku, Turku, Finland 13Department of Pediatrics, Turku University Hospital, Turku, Finland 14Department of Paediatrics, PEDEGO Research Unit, Medical Research Centre, University of Oulu, Oulu, Finland 15Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland 16Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden 17Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, 00290, Helsinki, Finland 18Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland 19Center for Child Health Research, Tampere University Hospital, Tampere, Finland |
| Format: | article |
| Version: | published version |
| Access: | open |
| Online Access: | PDF Full Text (PDF, 5.9 MB) |
| Persistent link: | http://urn.fi/urn:nbn:fi-fe2020110289008 |
| Language: | English |
| Published: |
Elsevier,
2020
|
| Publish Date: | 2020-11-02 |
| Description: |
AbstractCeliac disease (CD) is a systemic immune-mediated disorder with increased frequency in the developed countries over the last decades implicating the potential causal role of various environmental triggers in addition to gluten. Herein, we apply determination of perfluorinated alkyl substances (PFAS) and combine the results with the determination of bile acids (BAs) and molecular lipids, with the aim to elucidate the impact of prenatal exposure on risk of progression to CD in a prospective series of children prior the first exposure to gluten (at birth and at 3 months of age). Here we analyzed PFAS, BAs and lipidomic profiles in 66 plasma samples at birth and at 3 months of age in the Type 1 Diabetes Prediction and Prevention (DIPP) study (n = 17 progressors to CD, n = 16 healthy controls, HCs). Plasma PFAS levels showed a significant inverse association with the age of CD diagnosis in infants who later progressed to the disease. Associations between BAs and triacylglycerols (TGs) showed different patterns already at birth in CD progressors, indicative of different absorption of lipids in these infants. In conclusion, PFAS exposure may modulate lipid and BA metabolism, and the impact is different in the infants who develop CD later in life, in comparison to HCs. The results indicate more efficient uptake of PFAS in such infants. Higher PFAS exposure during prenatal and early life may accelerate the progression to CD in the genetically predisposed children. see all
|
| Series: |
Environmental research |
| ISSN: | 0013-9351 |
| ISSN-E: | 1096-0953 |
| ISSN-L: | 0013-9351 |
| Volume: | 188 |
| Article number: | 109864 |
| DOI: | 10.1016/j.envres.2020.109864 |
| OADOI: | https://oadoi.org/10.1016/j.envres.2020.109864 |
| Type of Publication: |
A1 Journal article – refereed |
| Field of Science: |
3142 Public health care science, environmental and occupational health |
| Subjects: | |
| Funding: |
This study was supported by funding from Vetenskapsrådet (to T.H.; grant no. 2016–05176) and Formas (to T.H. and M.O.; grant no. 2019–00869). The DIPP study was supported by the following grants: JDRF (grants 1-SRA-2016-342-M-R, 1SRA-2019-732-M-B); European Union (grant BMH4-CT98-3314); Novo Nordisk Foundation; Academy of Finland (Decision No 292538 and Center of Excellence in Molecular Systems Immunology and Physiology Research, 2012–2017, Decision No. 250114) and Special Research Funds for University Hospitals in Finland. The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. |
| Copyright information: |
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
|
https://creativecommons.org/licenses/by/4.0/ |